Connect Biopharma is trading 7% down now at $1.20 after continued selling related to its September 15 asthma-trial readout: rademikibart improved FEV1 by 130 mL versus placebo, but the Phase 2 study missed statistical significance on its primary 28-day treatment-failure endpoint.
- Shares closed at $1.29 on September 17 after falling 32.17% on September 15.
- Broader markets rallied, making the company-specific trial concern the clearer catalyst.